Sponsored by the Center for Law and the Biosciences. Featuring Michael Waitzkin.

Do financial conflicts of interest undermine the integrity of biomedical research? Can financial conflicts of interest be “managed” in an academic environment? Do universities have the capacity to conduct complex clinical trials in humans to test developing technologies? What insights do Penn’s and Wilson’s experience with the gene therapy program provide in considering these questions?

Michael B. Waitzkin (SLS ’74) is a partner at FoxKiser in Washington DC, which provides strategic counsel to the biomedical research community. He represented Dr. James M. Wilson, formerly Director of Penn’s Institute for Human Gene Therapy, in the legal and regulatory proceedings which followed a death in a Phase I clinical trial of gene therapy. Mr. Waitzkin was a Fellow in Law, Science & Medicine at Yale Law School, serves as a Senior Scholar at Duke’s Fuqua School of Business and is a member of the Board of Visitors of the Law School.

Related Media